Wip1 directly dephosphorylates gamma-H2AX and attenuates the DNA damage response.
The integrity of DNA is constantly challenged throughout the life of a cell by both endogenous and exogenous stresses. A well-organized rapid damage response and proficient DNA repair, therefore, become critically important for maintaining genomic stability and cell survival. When DNA is damaged, the DNA damage response (DDR) can be initiated by alterations in chromosomal structure and histone modifications, such as the phosphorylation of the histone H2AX (the phosphorylated form is referred to as gamma-H2AX). gamma-H2AX plays a crucial role in recruiting DDR factors to damage sites for accurate DNA repair. On repair completion, gamma-H2AX must then be reverted to H2AX by dephosphorylation for attenuation of the DDR. Here, we report that the wild-type p53-induced phosphatase 1 (Wip1) phosphatase, which is often overexpressed in a variety of tumors, effectively dephosphorylates gamma-H2AX in vitro and in vivo. Ectopic expression of Wip1 significantly reduces the level of gamma-H2AX after ionizing as well as UV radiation. Forced premature dephosphorylation of gamma-H2AX by Wip1 disrupts recruitment of important DNA repair factors to damaged sites and delays DNA damage repair. Additionally, deletion of Wip1 enhances gamma-H2AX levels in cells undergoing constitutive oncogenic stress. Taken together, our studies show that Wip1 is an important mammalian phosphatase for gamma-H2AX and shows an additional mechanism for Wip1 in the tumor surveillance network.
Cha
Hyukjin
H
Department of Biochemistry, Georgetown University, Washington, District of Columbia 20057-1468, USA. hjcha@cha.ac.kr
Lowe
Julie M
JM
Li
Henghong
H
Lee
Ji-Seon
JS
Belova
Galina I
GI
Bulavin
Dmitry V
DV
Fornace
Albert J
AJ
D000818:Animals; D015153:Blotting, Western; D001943:Breast Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D002478:Cells, Cultured; D003110:Colonic Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D020552:Comet Assay; D004249:DNA Damage; D004260:DNA Repair; D004622:Embryo, Mammalian / Q000378:metabolism / Q000473:pathology*; D005260:Female; D005347:Fibroblasts / Q000378:metabolism / Q000473:pathology*; D005455:Fluorescent Antibody Technique; D006657:Histones / Q000378:metabolism*; D006801:Humans; D047468:Immunoprecipitation; D007259:Infrared Rays; D051379:Mice; D016297:Mutagenesis, Site-Directed; D010749:Phosphoprotein Phosphatases / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D010766:Phosphorylation; D000071636:Protein Phosphatase 2C; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D034741:RNA, Small Interfering / Q000494:pharmacology; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014466:Ultraviolet Rays; D014965:X-Rays
C468783:H2AX protein, human; D006657:Histones; D012333:RNA, Messenger; D034741:RNA, Small Interfering; C000607458:PPM1D protein, human; D010749:Phosphoprotein Phosphatases; C000607468:Ppm1d protein, mouse; D000071636:Protein Phosphatase 2C
Curr Biol. 2000 Jul 27-Aug 10;10(15):886-95
10959836
Nat Genet. 2002 Jun;31(2):133-4
12021784
Curr Biol. 2002 Oct 29;12(21):1846-51
12419185
Clin Cancer Res. 2003 Jun;9(6):1995-2004
12796361
Cancer Metastasis Rev. 2008 Jun;27(2):123-35
18265945
Nat Genet. 2002 Jun;31(2):210-5
12021785
Science. 2004 Dec 17;306(5704):2084-7
15528408
Genomics. 2000 Mar 15;64(3):298-306
10756097
Cell. 2003 Aug 8;114(3):371-383
12914701
Carcinogenesis. 2007 Nov;28(11):2298-304
17615256
Nat Rev Cancer. 2008 Dec;8(12):957-67
19005492
Nature. 2006 Jan 26;439(7075):497-501
16299494
Oncogene. 2010 Apr 15;29(15):2281-91
20101220
Breast Cancer Res Treat. 2006 Feb;95(3):257-63
16254685
Mol Cell. 2004 Dec 22;16(6):979-90
15610740
Biochem Biophys Res Commun. 2007 Jun 29;358(2):650-4
17498657
EMBO Rep. 2008 Oct;9(10):1019-26
18758438
Cancer Res. 2003 Apr 15;63(8):1876-83
12702577
Cancer Biol Ther. 2005 Oct;4(10):1154-8
16258255
Clin Cancer Res. 2009 Apr 1;15(7):2269-80
19293255
Nature. 2003 Jan 30;421(6922):499-506
12556884
Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6048-53
9177166
Trends Cell Biol. 2009 May;19(5):207-17
19342239
J Biol Chem. 2009 Feb 27;284(9):5994-6003
19049966
J Neurooncol. 2008 Feb;86(3):245-56
17932621
Nature. 2005 Apr 14;434(7035):864-70
15829956
Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8173-8
12034884
Mol Cell. 2005 Dec 9;20(5):801-9
16310392
Proc Natl Acad Sci U S A. 2006 Jun 27;103(26):9891-6
16788066
Science. 2002 May 3;296(5569):922-7
11934988
Cell. 2003 Aug 8;114(3):359-70
12914700
Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):233-8
11756691
Cell. 2005 Dec 29;123(7):1213-26
16377563
Mol Cell. 2006 Sep 1;23(5):757-64
16949371
J Biol Chem. 2009 May 29;284(22):15193-205
19332536
Mol Cell. 2006 Jan 20;21(2):201-14
16427010
Nature. 2003 Feb 27;421(6926):961-6
12607005
Cell Death Differ. 2006 Jul;13(7):1170-80
16311512
Stem Cells. 2009 Aug;27(8):1963-75
19544416
Nat Genet. 2004 Apr;36(4):343-50
14991053
Oncogene. 2007 Dec 10;26(56):7773-9
18066090
Genes Dev. 2007 Jan 1;21(1):43-8
17210786
Cell. 2004 Dec 17;119(6):777-88
15607975
Mol Cell. 2008 Apr 11;30(1):86-97
18406329
Mol Cell Biol. 2002 Feb;22(4):1094-105
11809801
Breast Cancer Res Treat. 2007 Mar;101(3):269-78
16897432
Breast Cancer Res Treat. 2003 Apr;78(3):313-22
12755490
Immunol Res. 2008;42(1-3):29-40
18622584
Mol Cell. 2006 Jul 7;23(1):121-32
16818236
Science. 2008 Mar 7;319(5868):1352-5
18323444
Mol Carcinog. 2006 Aug;45(8):594-604
16652371
Oncogene. 2002 Dec 16;21(58):8967-80
12483513
Cell Cycle. 2005 Feb;4(2):339-45
15655354
Nucleic Acids Res. 2008 Oct;36(17):5678-94
18772227
J Biol Chem. 2010 Apr 23;285(17):12935-47
20118229